Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FDMT Captures Overall Composite Edge (42.1 HOLD vs 48.6 HOLD), While CRSP Leads 3–2 on Growth & Valuation Pillars

FDMT Overall Winner 6-Pillar Tally: FDMT 2 – 3 CRSP (1 Tie) Matrix Metrics: FDMT 3 – 7 CRSP

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -2058.6% operating margin) and revenue trajectory (+4505.6% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs CRSP
FDMT NASDAQ Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80

6-Pillar Scorecard Institutional Category Breakdown (FDMT 2 – 3 CRSP)

Columns: Metric · FDMT · CRSP
1. Valuation Multiples CRSP
Forward P/E N/M 23.4x
Trailing P/E N/M 23.4x
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% +1325.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $25M
Market Cap $669.3M $4.1B
3. Profitability & Quality CRSP
Gross Margin N/A N/A
Operating Margin -222.7% -2058.6%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -25.6%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$156M -$378M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRSP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 82.4% (10th %ile) 97.8% (52nd %ile)
Put/Call OI Skew 5.16x (Put-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (3) vs CRSP (7)
Institutional Metric FDMT CRSP Criterion Row Edge
Market Capitalization
Scale
$669.3M $4.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+4505.6% +1325.1% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% -2058.6% Higher Margin FDMT
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-56.7% -25.6% Higher ROE CRSP
52-Week Range Position
Momentum
47% ($7–$17) 1% ($40–$63) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 1.85β · 60% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$96M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +13.5 pp
FDMT: -4.04% · CRSP: -17.54%
3M Horizon FDMT +2.47 pp
FDMT: -20.86% · CRSP: -23.33%
6M Horizon FDMT +55.64 pp
FDMT: +39.27% · CRSP: -16.37%
1Y Horizon FDMT +33.87 pp
FDMT: +13.33% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue CRSP Revenue FDMT Op. Margin CRSP Op. Margin Margin Leader
FY2018 N/A $0M N/A -5087.8% CRSP
FY2019 $10M $290M -729.4% 16.1% CRSP
FY2020 $10M $0M -424.0% -49295.5% FDMT
FY2021 $20M $910M -395.5% 40.8% CRSP
FY2022 $0M $0M -3516.5% -56190.4% FDMT
FY2023 $20M $370M -544.6% -60.0% CRSP
FY2024 $0M $40M -507678.4% -1250.4% CRSP
FY2025 $90M $0M -187.2% -18933.6% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 3–7 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CRSP at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -2058.6% operating margin) and revenue trajectory (+4505.6% vs. +1325.1% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FDMT cumulative revenue shifted +800.0% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

CRSP screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.